Switzerland· 61263003
Simponi 100 mg, Injektionslösung in einer Fertigspritze
A golimumab product containing golimumabum, registered in Switzerland by Janssen-Cilag AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Golimumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AB06 (golimumab), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Golimumab · ATC L04AB06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- golimumabum
- Manufacturer
- Janssen-Cilag AG
- Country
- Switzerland (CH)
- ATC code
- L04AB06
- ATC class
- Golimumab
- Defined daily dose
- 1.66 mg, P
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin76806126300361 mlCHF 1446.85
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
429 interactions on record for golimumab.
Graded by severity as the source publishes them — 287 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Golimumab · interactions on record
429 records
- 287 severe
- 135 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Golimumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumSimponi 45 mg/0.45 mlJanssen-Cilag International
- CzechiaSIMPONIJanssen-Cilag International N.V., Beerse
- IcelandSimponiJanssen-Cilag International NV*
- PolandSimponiJanssen Biologics B.V.
- SwedenSimponi 45 mg/0,45 ml Injektionsvätska, lösning i förfylld injektionspennaJanssen-Cilag International NV
- FinlandGobivazAdvanz Pharma Limited
- IrelandGOBIVAZ 100 mg solution for injection in pre-filled penAdvanz Pharma Limited
- NetherlandsGOBIVAZ 100 mg oplossing voor injectie in een voorgevulde penAdvanz Pharma Limited
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Gotenfia
- Iceland · Gobivaz, Gotenfia
- Liechtenstein · Gobivaz, Gotenfia
- Norway · Gobivaz, Gotenfia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a94f3e1d-839c-4565-8b13-0d8c90c8d626 GET /v1/drugs/a94f3e1d-839c-4565-8b13-0d8c90c8d626?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "golimumabum 100 mg",
"valid_from": "2014-02-01",
"limitations": "[{\"description\":\"Die Behandlung mit Simponi bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes:<br>\\n<br>\\n<b>Rheumatoide Arthritis:</b> Zur subcutanen Behandlung der aktiven rheumatoiden Arthritis (nur in Kombination mit Methotrexat), wenn die vorausgegangene antirheumatische Standardtherapie mit krankheitsmodifizierenden Antirheumatika (DMARDs) unzulänglich war.<br>\\n<br>\\n<b>Psoriasis-Arthritis:</b> Zur subcutanen Behandlung der Psoriasis-Arthritis, wenn die vorausgegangene antirheumatische Standardtherapie mit krankheitsmodifizierenden Antirheumatika (DMARDs) unzulänglich war.<br>\\n<br>\\n<b>Morbus Bechterew/ Ankylosierende Spondylitis (AS):</b> Zur Behandlung des Morbus Bechterew/ Ankylosierende Spondylitis, wenn die vorausgegangene konventionelle Therapie unzulänglich war.<br>\\n<br>\\n<b>Moderate bis schwere Colitis ulcerosa:</b> Zur Behandlung erwachsener Patienten mit moderater bis schwerer Colitis ulcerosa, wenn die vorausgegangene konventionelle Therapie (z.B. mit Azathioprin, 6-Mercaptopurin oder Glukokortikoiden) unzulänglich war oder nicht vertragen wurde.<br>\\n<br>\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2020-12-01\"}]",
"galenic_form": "Inj Lös 100 mg/1ml",
"therapeutic_area": null,
"sl_inclusion_date": "2014-02-01",
"self_retention_pct": 10
}See everything about golimumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.